Biocept and UT Southwestern Announce Liquid Biopsy Clinical Study to Profile Lung Cancer Patients

Biocept, Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical Center (UT Southwestern Medical Center). Led by recognized oncologist and ALK mutation researcher Dr. Saad Khan, the study is designed to evaluate the clinical utility of Biocept’s Target Selector™ platform for patients diagnosed with ALK-positive non-small cell lung cancer and treated with ALK-inhibitor therapy. A second arm of the study will evaluate patients with rare cancers such as anaplastic thyroid cancer to determine if driver mutations such as ALK rearrangements can be identified and treated with targeted therapy to improve patient outcomes.

“Identifying ALK rearrangements in patients with lung cancer has become important as new targeted therapies are available to help manage disease in patients harboring this type of alteration,” said Saad Khan, MD, Medical Oncologist and Assistant Professor of Internal Medicine at UT Southwestern Medical Center. “We have designed this study to demonstrate the ability to rapidly identify ALK rearrangements, and to provide further evidence that patients with both non-small cell lung cancer and rare cancers harboring ALK alterations can benefit from targeted therapy and serial monitoring of ALK and other key alterations.”

“Demonstrating the clinical utility of our Target Selector™ platform in studies conducted by top researchers like Dr. Khan is important to expand the clinical adoption of our liquid biopsy offering in oncology,” said Biocept’s President and Chief Executive Officer Michael Nall. “We continue to evaluate our Target Selector™ platform in clinical studies in which the identification of ALK fusions and other alterations with our assays can help guide treatment decisions resulting in improved patient outcomes. Our Target Selector™ tests can be used to help physicians rapidly obtain the actionable information they need to design personalized treatment plans for their cancer patients.”

Source – PR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *

*